Syngene International (SYNGENE) Q2 24/25 earnings summary

Executive summary

• Q2 and H1 FY2025 performance was broadly flat year-over-year, with sequential revenue growth of 13% in Q2 and early signs of recovery in discovery services.

• Discovery Services showed recovery, driven by pilot projects and increased client engagement, especially from biopharma clients seeking alternatives to China.

• Biologics business and process development projects in small molecules showed good traction, with new manufacturing capacity coming online in H2.

• Leadership transition underway, with Deepak Jain taking over as CFO.

• Unaudited financial results for Q2 and H1 FY25 were reviewed and approved by the Board, with unqualified limited review reports.

Financial highlights

• Q2 FY25 revenue from operations: INR 8,910 million, down 2% YoY, but up 13% sequentially; H1 FY25 revenue: INR 16,807 million, down 2% YoY.

• Q2 FY25 PAT after exceptional items: INR 1,061 million, down 9% YoY; H1 FY25 PAT after exceptional items: INR 1,818 million, down 13% YoY.

• Q2 FY25 EBITDA margin: 28.8%; H1 FY25 EBITDA margin: 26.2%.

• Staff costs increased 12% YoY in Q2 FY25, while material costs declined 11%.

• Net cash position at INR 8,648 million as of September 30, 2024.

Outlook and guidance

• Revenue growth for FY2025 expected in the high single to low double digits, with momentum building in H2.

• Growth expected across discovery, development, and manufacturing segments in H2.

• Biologics manufacturing facility (Unit III) on track to begin operations in H2 FY25, supporting future growth.

• Full-year margins anticipated to be around last year's level, with margin recovery in H2.

• Revenue growth likely at the lower end of the guidance range.